Sangamo Therapeutics, Inc., a genomic medicine company, announced the pricing of a $23.0 million underwritten offering. The offering comprises 12,235,000 shares of common stock and pre-funded warrants to purchase 34,398,393 shares, along with accompanying warrants to purchase 46,633,393 shares of common stock. Each share of common stock and accompanying warrant is priced at $0.50, while each pre-funded warrant and accompanying warrant is priced at $0.49. Warrants have an exercise price of $0.75 per share, becoming exercisable six months post-issuance with a six-year expiry. The offering is expected to conclude around May 14, 2025, with the proceeds aimed at working capital and general corporate purposes. Cantor is acting as the sole book-running manager for the offering.